B

Beam Therapeutics

D
BEAM
USD
-0.91
(-3.7619%)
Market Closed
10,933.00
Volume
-4.635
EPS
-
Div Yield
-14.370370
P/E
1,918,635,610.32
Market Cap
Today
-3.7619%
1 Week
-12.776%
1 Month
-8.724%
6 Months
-39.201%
12 Months
-5.558%
Year To Date
-14.380%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
G
GRIN
-0.025
(-0.1757%)
USD
E
ECC
-0.02
(-0.1994%)
USD

Title:
Beam Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making adouble-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Do you need help or have a question?
Contact Us